DOCSLIB.ORG

The Prevention of Substance Use, Risk and Harm in Australia

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Prevention of Substance Use, Risk and Harm in Australia wyxyqer ri2iixsyx2yp fexgi2 iD2su2exh rew2sx2e evse 2review2of2the2evidene wsxsisev2gy xgsv2yx2h q2eiq he2xtionl2hrug2eserh2snstitute2nd2the2gentre2for2edolesent2relth ri2iixsyx2yp2 fexgi iD2su2exh2rew2sx e evseX 2review2of2the2evidene endy2voxleyD2tohn2F2oumourouD2im2tokwellD2fen2rinesD utie2ottD2geli2qodfreyD2ilizeth2tersD2qeorge2ttonD ihrd2pordhmD2hennis2qryD2tnn2wrshllD hvid2yderD2herry2ggersD2ven2ni2nd2to2illims wyxyqer ith2ontriutions2yX usn2grruthersD2ny2ghikritzhsD2imon2ventonD2ihrd widfordD2mel2now2nd2gtherine2pooner his2work2ws2funded2y2the2eustrlin qovernment2heprtment2of2relth2nd egeing tnuryD2PHHR © Commonwealth of Australia 2004 ISBN: 0 642 82482 7 This work is copyright. Apart from any use as permitted under the Copyright Act 1968, no part may be reproduced by any process without prior written permission from the Commonwealth available from the Australian Government Department of Communications, Information Technology and the Arts. Requests and inquiries concerning reproduction and rights should be addressed to the Commonwealth Copyright Administration, Intellectual Property Branch, Australian Government Department of Communications, Information Technology and the Arts, GPO Box 2154, Canberra ACT 2601 or posted at <http://www.dcita.gov.au/cca>. The National Drug Research Centre and the Centre for Adolescent Health The Prevention of Substance Use, Risk and Harm in Australia: a review of the evidence Wendy Loxley, John W Toumbourou, Tim Stockwell, Ben Haines, Katie Scott, Celia Godfrey, Elizabeth Waters, George Patton, Richard Fordham, Dennis Gray, Jann Marshall, David Ryder, Sherry Saggers, Lena Sanci and Jo Williams with contributions by Susan Carruthers, Tanya Chikritzhs, Simon Lenton, Richard Midford, Pamela Snow and Catherine Spooner Publication approval number: 3475/JN8607 Design: Themeda Printing: Union Offset This research paper does not necessarily reflect the policy position of the Australian Government. gyxix eguxyvihqiwix FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFix effiseih2iw FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFx iig si2 wwe FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFF xiii e2IX2sxyh gsyx FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFF I grei2IX2sxyh gsyx FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFF Q IFI2he2xtionl2hrug2trtegy2@xhA FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFF Q IFP2he2sope2of2the2wonogrph FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFF R IFQ2tterns2of2drug2use2nd2drugErelted2hrm FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFF R IFR2erspetives2on2prevention FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFF T IFS2ionomi2evlutions2of2lohol2nd2drug2interventions FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFF U IFT2he2legl2sttus2of2drugs FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFF V grei2PX2wiryh FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFII PFI2ummry FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFF II PFP2sntrodution FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFII PFQ2tterns2of2use FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFII PFR2rrms FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFII PFS2oil2determinnts FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFIP PFT2isk2nd2protetive2ftors FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFIP PFU2snterventions2litertureFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFIQ e2PX2eix2yp2 fexgi2 i2exh2rew FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFF IW grei2QX2eix2yp2h q2 iD2su2exh2rew2sx2ri2iev2ie FFFFFFFFFFFFFFFFFFFFFFFFFFFFFIW QFI2ummry FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFF IW QFP2snfluene2of2prents2drug2use2during2pregnny2nd2erly2hildhood FFFFFFFFFFFFFFFFFFFFFFFFFFFIW QFQ2tterns2of2drug2use2nd2hrm2mong2dolesentsFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFPQ QFR2vongitudinl2ptterns2of2use2from2dolesene2to2dulthood FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFPS QFS2vongitudinl2ptterns2of2hrm2from2dolesent2drug2use FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFPU iii grei2RX2eix2yp2h q2 iD2su2exh2rew2sx2ri2qixiev2y vesyx exh2 fEy vesyx FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFQI RFI2ummry FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFF QI RFP2tterns2of2drug2useD2risk2nd2hrm2in2the2eustrlin2popultion FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFQP RFQ2edult2ptterns2of2drug2useD2risk2nd2hrm FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFQS RFR2tterns2of2drug2useD2risk2nd2hrm2mong2older2eustrlins FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFRQ RFS2tterns2of2drug2use2risk2nd2hrm2mong2sndigenous2eustrlins FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFRS RFT2tterns2of2drug2use2risk2nd2hrm2mong2ulturlly2nd2linguistilly diverse2@gevhA2eustrlins FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFRW RFU2he2ssoition2of2drug2use2nd2mentl2helth2prolems FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFSH RFV2tterns2of2drug2useD2risk2nd2hrm2mong2polie2detinees2nd2prisoners FFFFFFFFFFFFFFFFFFFSI RFW2smpts2on2the2roder2ommunity FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFSP e2QX2ygsev2hiiwsxexD2su2exh2yigsyx2pegyFFFFFFFFFFFFFFFFFFFFFF TI grei2SX2ygsev2hiiwsxex2yp2rievr2exh22h q2 i FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFF TI SFI2ummry FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFF TI SFP2sntrodution FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFTI SFQ2he2soil2determinnts2of2helth FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFTP SFR2gonlusion FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFTW grei2TX2su2exh2yigsi2pegy2ihsgsxq2rewp v2h q2 i FFFFFFFFFFFFFFFFFFFFFFFFUI TFI2ummry FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFF UI TFP2sntrodution FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFUI TFQ2revention2sieneX22developmentl2pthwys2pproh2to2prevention FFFFFFFFFFFFFFFFFFFFFFFFUP TFR2ulity2of2evidene FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFUQ TFS2rior2to2irthFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFUR TFT2snfny2nd2preEshool FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFUU TFU2rimry2shool2@ges2S2to2IIA FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFF UV TFV2eondry2shool2@ges2IP2to2IUA FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFVH TFW2edulthood2@ges2IV2to2TRA FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFF VT TFIH2etirement2nd2old2ge2@ges2TSCA FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFF VV TFII2he2umultive2influene2of2elevted2risk2ftors2nd2depressed protetive2ftors FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFVV TFIP2here2should2we2trget2prevention2effortsc2iskD2protetion2nd2the prevention2prdox FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFWH iv iixsyx2yp2 fexgi2 i2su2exh2rew2sx2e evse e2RX2ri2ishixgi2fei2py2iixsyx2sX2pyw2iev grsvhryyh2y2ehyvigixgi FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFF WQ grei2UX2grsvhryyh2sxiixsyx FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFWS UFI2ummry FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFF WS UFP2rior2to2irth FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFWT UFQ2snfny2nd2erly2hildhood2@ges2H2to2RA FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFWU UFR2rimry2shool2@ges2S2to2IIA FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFF IHP UFS2gonlusionshildhood2intervention FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFF IIH grei2VX2sxiixsyx2py2ehyvigix FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFF III VFI2ummry FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFF
Load more

Recommended publications
  • DRUGGED DRIVING CONFERENCE Poly Drug
    DRUGGED DRIVING CONFERENCE February 1 – 4, 2021 Phoenix, Arizona Poly Drug Use Presented by: Tom Humphrey Department of Public Safety & Dennis Milius Sergeant, Department of Public Safety Distributed by: ARIZONA PROSECUTING ATTORNEYS’ ADVISORY COUNCIL 3838 N. Central Ave, Suite 850 Phoenix, Arizona 85012 ELIZABETH BURTON ORTIZ EXECUTIVE DIRECTOR Poly Drug Use – Drug Combinations Poly Drug Use: When a person ingests drugs from two or more different drug categories. The body will exhibit a combination of effects. Poly Drug cases can be some of the more difficult cases for the DRE to evaluate. Due to the fact that the defendant has multiple drugs in his/her system, however, there may be less jury appeal for the defendant. Accordingly, they may be easier to prosecute. Note: the crime lab may only quantify some or even none of the drugs. At times the lab cannot test for all of the drugs in the system due to insufficient blood or lack of testing methods. In most cases, this should not prevent us from proceeding on the case. Alcohol is a drug. It is the most common drug used in combination with other drugs. Alcohol combined with cannabis/marijuana is currently the most common drug combination we see in Arizona. Potential Effects of Poly Drug Use Four types of combined effects can, and generally will, occur when two or more drug categories are used together: • Null Effect • Overlapping Effect • Additive Effect • Antagonistic Effect Types of Combined Effects Null Effect The simplest way to explain the null effect is using the phrase: "zero + zero = zero" Example: when a subject consumes one drug, which does not cause HGN, and they ingest another drug, which does not cause HGN, then the officer should not expect to see HGN.
    [Show full text]
  • Epidemics of HIV, HCV and Syphilis Infection Among Synthetic Drugs
    www.nature.com/scientificreports OPEN Epidemics of HIV, HCV and syphilis infection among synthetic drugs only users, heroin-only users and Received: 7 November 2017 Accepted: 28 March 2018 poly-drug users in Southwest China Published: xx xx xxxx Shu Su1, Limin Mao 2, Jinxian Zhao3, Liang Chen3, Jun Jing4, Feng Cheng4 & Lei Zhang 1,4,5 The number of poly-drug users who mix use heroin and synthetic drugs (SD) is increasing worldwide. The objective of this study is to measure the risk factors for being infected with hepatitis C (HCV), human immunodefciency virus (HIV) and syphilis among SD-only users, heroin-only users and poly- drug users. A cross-sectional study was conducted in 2015 from a national HIV surveillance site in Southwest China, 447 poly-drug, 526 SD-only and 318 heroin-only users were recruited. Poly-drug users have higher drug-use frequency, higher rates of drug-sharing and unsafe sexual acts than other users (p < 0.05). About a third (36.7%) of poly-drug users experienced sexual arousal due to drug efects, which is higher than the rate among other drug users. Poly-drug users had the highest prevalence of HIV (10.5%) and syphilis (3.6%), but heroin-only users had the highest prevalence of HCV (66.0%) (all p < 0.05) among three groups. Logistic regression shows among poly-drug users, having sex following drug consumption and using drugs ≥1/day were the major risk factors for both HIV (Adjusted odds ratio (AOR) = 2.4, 95% CI [1.8–3.4]; 2.3, [1.6–3.1]) and syphilis infection (AOR = 4.1, [2.1–6.9]; 3.9, [1.8–5.4]).
    [Show full text]
  • MDMA ('Ecstasy'): a Review of Its Harms and Classification Under the Misuse of Drugs Act 1971
    MDMA (‘ecstasy’): A REVIEW OF ITS HARMS AND CLASSIFICATION UNDER THE MISUSE OF DRUGS ACT 1971 Advisory Council on the Misuse of Drugs ACMD Advisory Council on the Misuse of Drugs 3rd Floor (SW), Seacole Building 2 Marsham Street London SW1P 4DF February 2008 Rt Hon Jacqui Smith MP Home Office 2 Marsham Street London SW1P 4DF Dear Home Secretary, The Advisory Council on the Misuse of Drugs (ACMD) recently considered that a review of MDMA (‘ecstasy’) would be timely as there is a much greater body of evidence regarding the harms and misuse of MDMA since the Council last provided its advice to Ministers in 1996. I have pleasure in enclosing the Council’s report. The use of MDMA is undoubtedly harmful. I would therefore like to emphasise that the Council continues to be concerned about the widespread use of MDMA; particularly among young people. Due to its prevalence of use, MDMA is a significant public health issue and we believe that criminal justice measures will only have limited effect. You will wish to note that the Council strongly advises the promulgation of public health messages. It is of vital importance that issues of classification do not detract from messages concerning public health. Forensic evidence shows that MDMA is by far the most commonly seized of the ‘ecstasy-like’ drugs. MDMA is presently generically classified in Class A under the Misuse of Drugs Act with other ‘ecstasy-like’ drugs. The ACMD has not extended this review to other compounds within the generic classification since their use is considerably less than that of MDMA.
    [Show full text]
  • Civil Society Monitoring of Harm Reduction in Europe, 2019
    Correlation Correlation European DATA REPORT Eropean Harm Reduction R C Network C Network CIVIL SOCIETY MONITORING OF HARM REDUCTION IN EUROPE, 2019 DATA REPORT 1 CIVIL SOCIETY MONITORING OF HARM REDUCTION IN EUROPE, 2019 ® Correlation – European Harm Reduction Network, 2019. This publication of Correlation – European Harm Reduction Network is protected by copyright. Reproduction is authorised provided the source is acknowledged. Recommended citation: Tammi, T., Rigoni, R., Matičič, M., Schäffer, D., van der Gouwe, D., Schiffer, K., Perez Gayo, R., Schatz, E. (2020): Civil Society Monitoring of Harm Reduction in Europe, 2019. Data Report. Correlation European Harm Reduction Network, Amsterdam. Correlation – European Harm Reduction Network c/o Foundation De REGENBOOG GROEP Droogbak 1d 1013 GE Amsterdam The Netherlands www.correlation-net.org This project has been supported by the European Commission. Correlation - European Harm Reduction Network is co-funded by the European Union 2 Correlation European DATA REPORT Harm Reduction C Network CIVIL SOCIETY MONITORING OF HARM REDUCTION IN EUROPE, 2019 DATA REPORT 3 CIVIL SOCIETY MONITORING OF HARM REDUCTION IN EUROPE, 2019 CONTRIBUTORS Editor: The data network: Graham Shaw Albania: Genci Mucollari, Aksion Plus Austria: Alexandra Karden & Barbara Siokola, Scientific expert group: Suchthilfe Wien Tuukka Tammi (THL), Dagmar Hedrich (EMCDDA), Belgium: Peter Blanckaert & Tessa Windelinckx, Sam Shirley-Beavan (HRI), Perrine Roux (INSERM). Free Clinic Bosnia and Herzegovina: Samir Ibisevic, PROI
    [Show full text]
  • Recent Changes in Drug Abuse Scenario the Novel Psychoactive Substances (NPS) Phenomenon
    brain sciences Recent Changes in Drug Abuse Scenario The Novel Psychoactive Substances (NPS) Phenomenon Edited by Fabrizio Schifano Printed Edition of the Special Issue Published in Brain Sciences www.mdpi.com/journal/brainsci Recent Changes in Drug Abuse Scenario Recent Changes in Drug Abuse Scenario The Novel Psychoactive Substances (NPS) Phenomenon Special Issue Editor Fabrizio Schifano MDPI • Basel • Beijing • Wuhan • Barcelona • Belgrade Special Issue Editor Fabrizio Schifano University of Hertfordshire UK Editorial Office MDPI St. Alban-Anlage 66 4052 Basel, Switzerland This is a reprint of articles from the Special Issue published online in the open access journal Brain Sciences (ISSN 2076-3425) in 2018 (available at: https://www.mdpi.com/journal/brainsci/ special issues/drug abuse scenario) For citation purposes, cite each article independently as indicated on the article page online and as indicated below: LastName, A.A.; LastName, B.B.; LastName, C.C. Article Title. Journal Name Year, Article Number, Page Range. ISBN 978-3-03897-507-6 (Pbk) ISBN 978-3-03897-508-3 (PDF) c 2019 by the authors. Articles in this book are Open Access and distributed under the Creative Commons Attribution (CC BY) license, which allows users to download, copy and build upon published articles, as long as the author and publisher are properly credited, which ensures maximum dissemination and a wider impact of our publications. The book as a whole is distributed by MDPI under the terms and conditions of the Creative Commons license CC BY-NC-ND. Contents About the Special Issue Editor ...................................... vii Fabrizio Schifano Recent Changes in Drug Abuse Scenarios: The New/Novel Psychoactive Substances (NPS) Phenomenon Reprinted from: Brain Sci.
    [Show full text]
  • Licit and Illicit Drug Use During Pregnancy: Maternal, Neonatal and Early Childhood Consequences
    SUBSTANCE ABUSE IN CANADA 2013 Licit and Illicit Drug Use during Pregnancy: Maternal, Neonatal and Early Childhood Consequences By Loretta Finnegan With A Call to Action by Franco Vaccarino and Colleen Dell This document was published by the Canadian Centre on Substance Abuse (CCSA). CCSA activities and products are made possible through a financial contribution from Health Canada. The views of CCSA do not necessarily represent the views of the Government of Canada. The subjects in the photographs used throughout this publication are models who have no relation to the content. The vignettes are fictional and do not depict any actual person. Suggested citation: Finnegan, L. (2013). Substance abuse in Canada: Licit and illicit drug use during pregnancy: Maternal, neonatal and early childhood consequences. Ottawa, ON: Canadian Centre on Substance Abuse. © Canadian Centre on Substance Abuse 2013. CCSA, 75 Albert St., Suite 500 Ottawa, ON K1P 5E7 Tel.: 613-235-4048 Email: [email protected] This document can also be downloaded as a PDF at www.ccsa.ca. Ce document est également disponible en français sous le titre : Toxicomanie au Canada 2013 : Consommation de drogues licites et illicites pendant la grossesse : Répercussions sur la santé maternelle, néonatale et infantile ISBN 978-1-77178-041-4 Licit and Illicit Drug Use during Pregnancy: Maternal, Neonatal and Early Childhood Consequences Prepared for the Canadian Centre on Substance Abuse Loretta P. Finnegan, M.D., LLD, (Hon.), ScD (Hon.); President, Finnegan Consulting, LLC; Professor of Pediatrics, Psychiatry and Human Behavior, Thomas Jefferson University (Retired); Founder and Former Director of Family Center, Comprehensive Services for Pregnant Drug Dependent Women, Philadelphia, PA; Former Medical Advisor to the Director, Office of Research on Women’s Health, National Institutes of Health, U.S.
    [Show full text]
  • Illegal Drugs - the Facts 1 Contents Introduction
    what you need to know teacher version For more information see www.positi vechoices.org.au Illegal Drugs - The Facts 1 contents Introduction .............................................................................................................. 3 What are illegal drugs? ......................................................................................... 3 How many people use illegal drugs in Australia ........................................ 4 Illegal drugs and the law ...................................................................................... 5 Why do young people use drugs? .................................................................... 6 How teachers can guide their students against drug use and related harms ................................................................................................... 7 Talking to a young person about illegal drugs ............................................ 8 How to help someone who has taken a drug ............................................ 10 DRS-ABCD: Basic life support fl ow chart ......................................... 13 Recovery position ....................................................................................... 14 Evidence-based drug education programs: Australia .......................... 15 Evidence-based drug education programs: International .................. 19 Cannabis ................................................................................................................... 23 Pills and Ecstasy ...................................................................................................
    [Show full text]
  • Poly-Product Drug Use Disparities in Adolescents of Lower Socioeconomic Status Emerging Trends in Nicotine Products, Marijuana
    Behaviour Research and Therapy 115 (2019) 103–110 Contents lists available at ScienceDirect Behaviour Research and Therapy journal homepage: www.elsevier.com/locate/brat Poly-product drug use disparities in adolescents of lower socioeconomic T status: Emerging trends in nicotine products, marijuana products, and prescription drugs Mariel S. Belloa, Rubin Khoddama, Matthew D. Stoneb, Junhan Choc, Yoewon Yoond, ∗ Jungeun Olivia Leed, Adam M. Leventhala,b, a University of Southern California, Department of Psychology, 3620 South McClintock Avenue, SGM 501, Los Angeles, CA, 90089, USA b University of California, San Diego School of Medicine, Department of Family Medicine and Public Health, 9500 Gilman Drive, La Jolla, CA, 92093, USA c University of Southern California Keck School of Medicine, Department of Preventive Medicine, 2001 North Soto Street, 3rd Floor, Los Angeles, CA, 90032-9045, USA d University of Southern California, Suzanne Dworak-Peck School of Social Work, 669 W 34th St, Los Angeles, CA, 90089, USA ARTICLE INFO ABSTRACT Keywords: Greater diversification of nicotine products, marijuana products, and prescription drugs have contributed to Health disparities increasing trends in adolescent poly-product use—concurrent use of 2 or more drugs—within these drug classes Socioeconomic status (e.g., nicotine use via e-cigarettes, hookah, cigars). Extant work suggests that poly-product drug use disparities Subjective social status may be disproportionately heightened among youth from lower socioeconomic status (SES) backgrounds, Substance use however, it is unknown whether indicators of objective SES or subjective SES differentially increase risk of poly- Poly-product use product use including these newly emerging drugs. This study examined associations of parental education and Adolescents subjective social status (SSS: perceptions of social standing compared to society [societal SSS] or school [school SSS]) with poly-product use of nicotine products, marijuana products, and prescription drugs among adolescents (N = 2218).
    [Show full text]
  • BOOKLET 4 Drugs and Associated Issues Among Young People and Older People PREFACE
    DRUGS AND AGE Drugs and associated issues among young people and older people ISBN 978-92-1-148304-8 WORLD DRUG 9 789211 483048 REPORT 2018 4 © United Nations, June 2018. All rights reserved worldwide. ISBN: 978-92-1-148304-8 eISBN: 978-92-1-045058-4 United Nations publication, Sales No. E.18.XI.9 This publication may be reproduced in whole or in part and in any form for educational or non-profit purposes without special permission from the copyright holder, provided acknowledgement of the source is made. The United Nations Office on Drugs and Crime (UNODC) would appreciate receiving a copy of any publication that uses this publication as a source. Suggested citation: World Drug Report 2018 (United Nations publication, Sales No. E.18.XI.9). No use of this publication may be made for resale or any other commercial purpose whatsoever without prior permission in writing from UNODC. Applications for such permission, with a statement of purpose and intent of the reproduction, should be addressed to the Research and Trend Analysis Branch of UNODC. DISCLAIMER The content of this publication does not necessarily reflect the views or policies of UNODC or contributory organizations, nor does it imply any endorsement. Comments on the report are welcome and can be sent to: Division for Policy Analysis and Public Affairs United Nations Office on Drugs and Crime PO Box 500 1400 Vienna Austria Tel: (+43) 1 26060 0 Fax: (+43) 1 26060 5827 E-mail: [email protected] Website: https://www.unodc.org/wdr2018 PREFACE Both the range of drugs and drug markets are Drug treatment and health services continue to fall expanding and diversifying as never before.
    [Show full text]
  • Non -Fatal Overdose Among People Who Inject Drugs in Tehran, Iran
    Noroozi et al. Substance Abuse Treatment, Prevention, and Policy (2020) 15:80 https://doi.org/10.1186/s13011-020-00323-0 RESEARCH Open Access Non -fatal overdose among people who inject drugs in Tehran, Iran Mehdi Noroozi1, Peter Higgs2, Azadeh Bayani3, Bahram Armoon4* , Ali Nazeri Astaneh5, Ladan Fattah Moghaddam6 and Mohammad Askari7 Abstract Background: With increasing frequencies of non-fatal overdose in people who inject drugs (PWID), it is essential to improve our knowledge about associated risk factors for overdose to inform overdose prevention and assistance programs. The aim of present study was to determine the prevalence of non-fatal overdose and the associated risk factors among PWID in Tehran, Iran. Methods: Snowball sampling was used to collect data from 465 participants in Tehran using a cross-sectional survey. Consenting participants who reported drug injecting in the past month and were able to speak and comprehend Farsi enough to respond to survey questions were interviewed. The endpoint of interest was non-fatal overdose in the previous 6 months, or answering “Yes” to the question: “In the last six months, have you ever overdosed by accident? (at least once)”. We used STATA v. 14 for this analysis. Statistical significance was defined as p < 0.05 for all analyses. Results: Of 465 PWIDs who participated in this study, all were male, and about half had less than a high school education. The prevalence of self-reported non-fatal overdose in the past 6 months was 38% (CI95%: 34, 43%). Our findings indicate that characteristics and behaviors that were associated with an increased risk of experiencing an overdose in the past 6 months were drug use initiation under 22 years (AOR =2.2, P < 0.05), using methamphetamine (AOR =2.8, P<0.05), and using multiple drugs at the same time (AOR =2.1, P<0.05).
    [Show full text]
  • Downloaded 09/26/21 04:47 PM UTC Ona What, If Any, Extra-Pharmacological Factors Are Commonly SECTION 1 Related to the Adverse Reaction Known As a Bad Trip
    ORIGINAL ARTICLE Journal of Psychedelic Studies 2(1), pp. 53–60 (2018) DOI: 10.1556/2054.2018.001 First published online March 20, 2018 Inside bad trips: Exploring extra-pharmacological factors GENÍS ONA* Department of Anthropology, Rovira i Virgili University, Tarragona, Spain (Received: June 18, 2017; revised manuscript received: January 16, 2018; accepted: January 17, 2018) Objective: This study aimed to clarify the influence of extra-pharmacological factors in the etiology of bad trips,a common adverse reaction related to the consumption of psychedelic drugs. Methods: A descriptive approach was adopted. The information was collected using a web-based survey. The survey respondents volunteered to participate based on the condition that they had suffered a bad trip in the past. Results: This report reveals some variables that are commonly related to this adverse reaction (i.e., the recreational consumption of drugs, the consumption of drugs in large, open outdoor spaces, or being inexperienced with the drug). In addition, we note that some problems, which may be related to bad trips (i.e., mixing drugs, ignorance about the purity, or the dosage), can be solved through harm- reduction strategies. Conclusions: We found certain aspects that could be related to the appearance of a bad trip, but it is not possible to establish a causal connection. We recommend conducting prospective studies with larger samples to collect more information about the role of extra-pharmacological factors. Keywords: psychedelic, bad trip, drug, adverse reaction
    [Show full text]
  • Prevalence of Psychoactive Drug Use Among Medical Students in A
    ORIGINAL ARTICLE J Nepal Med Assoc 2020;58(230):717-20 CC CC BY BY doi: 10.31729/jnma.5237 Prevalence of Psychoactive Drug Use among Medical Students in a Medical College of Nepal Jyoti Tara Manandhar Shrestha,1 Saurabh Tiwari,2 Dilip Kumar Kushwaha,2 Pratigya Bhattarai,1 Risu Raj2 1Department of Pharmacology, Kathmandu University School of Medical Sciences, Dhulikhel, Nepal, 2Kathmandu University School of Medical Sciences, Dhulikhel, Nepal. ABSTRACT Introduction: Psychoactive drug is a worrisome and emerging global problem. This is a disturbing matter, especially in the case of medical students, as it affects not only their health and academic performance alone but their clinical efficiency as well. This study aims to determine the prevalence of psychoactive drug use among medical students in a medical college in Nepal. Methods: A descriptive cross-sectional study was conducted after receiving ethical clearance from the Institutional Review Committee (Ref: 258/19) among undergraduate medical students from December 2019 to June 2020. Convenience sampling was used to collect data. Data analysis was done in the Statistical Package for Social Sciences. Point estimate at 95% confidence interval was calculated along with frequency and proportion for binary data. Results: The prevalence of psychoactive drug abuse was found to be 76 (44.2%) [CI= 43.6%– 44.8%]. The study showed males 59 (59%) were more indulged in abuse than females 17 (23.6%). Alcohol 72 (41.86%) was the most commonly used, then was tobacco 24 (13.95%) followed by cannabis 17(9.88%). Only two students were sedative and opioid abusers. Pleasure 38 (31.70%) and experimentation 29 (24.20%) were the two major causes of substance abuse.
    [Show full text]